Compare Amphastar Pharmaceuticals Inc (AMPH) vs Fabrinet (FN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Fabrinet (FN) trades at $471.13, down 2.41% over 24 hours, with technical indicators signaling a bearish short-term trend. The stock shows strong fundamentals, with Q1 2026 EPS of $3.72 beating estimates of $3.56, continuing a pattern of earnings outperformance. Revenue growth is robust, projected to rise from $3.42B in 2025 to $4.2B in 2026, while net income margin improves to 9.94%. Analyst sentiment remains highly bullish with a consensus price target of $733.00, though the stock faces near-term technical headwinds and premium valuation multiples.

Fabrinet's outlook is supported by its strategic position in the AI optical supply chain and consistent earnings beats, offering significant upside relative to analyst targets. Key risks include high valuation metrics, datacom supply constraints, and foreign exchange exposure. The stock presents a compelling growth opportunity for investors comfortable with its premium pricing, provided operational execution remains strong amid competitive and macroeconomic challenges.